FDA approves Johnson & Johnson's nasal spray for depression as standalone treatment
1. FDA approves Spravato as a standalone treatment for major depressive disorder. 2. Spravato sales reached $780 million in 2024, with expectations of $1-$5 billion annually. 3. One-third of U.S. adults with depression can benefit from this treatment innovation. 4. Spravato provides rapid symptom relief, differentiating it from standard antidepressants. 5. The drug's approval enhances J&J's portfolio amidst potential patent expirations.